Prostate Cancer Clinical Trials (July 2026): ~1,000 Recruiting Interventional Studies

Last updated: July 1, 2026

Current Clinical Trial Landscape

Recruiting Trials by Disease Stage

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

ADT + AR-pathway inhibitor ± docetaxel is standard. Trials explore intensification and PSMA-based approaches:

• Triplet therapy / intensification:
  • NCT06931340 - ADT + Apalutamide ± Docetaxel in metastatic prostate cancer (Phase 3)
  • NCT05983783 - Rezvilutamide + ADT + Docetaxel vs Rezvilutamide + ADT in mHSPC (Phase 3)
  • NCT07241416 - Rezvilutamide in mHSPC (Phase 3)
• PSMA-directed in mHSPC:
  • NCT06496581 - PEACE6: SOC ± 177Lu-PSMA-617 in de novo mHSPC with poor PSA response (Phase 3)
• De-escalation:
  • NCT07260435 - Shorter treatment with ARPI in low-volume mHSPC (Phase 3)
• Suboptimal response:
  • NCT06592924 - Adding docetaxel to ARPI in mCSPC with suboptimal PSA response (Phase 3)
• Platform trial:
  • NCT06320067 - Randomised platform trial testing treatments in mHSPC (Phase 3)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The most active research area in 2026. Phase 3 trials span bispecifics, PSMA radioligands (now including alpha-emitter 225Ac), AR-pathway intensification, and new ADCs:

• Bispecific T-cell engagers:
  • NCT07213674 - Xaluritamig (STEAP1xCD3) + Abiraterone vs investigator's choice in chemo-naive mCRPC (Phase 3)
  • NCT07164443 - Pasritamig (PSMAxCD3) vs Placebo in late-line mCRPC (Phase 3)
  • NCT07225946 - Pasritamig + Docetaxel vs Docetaxel in mCRPC (Phase 3)
• Next-gen AR-targeted:
  • NCT06136650 - Opevesostat (CYP11A1 inhibitor, MK-5684) vs alternative NHA in mCRPC post one NHA (Phase 3)
  • NCT06629779 - Mevrometostat (PF-06821497, EZH2 inhibitor) + Enzalutamide vs Enzalutamide alone in ARSi-naive mCRPC (Phase 3)
  • NCT03851640 - HC-1119 (next-gen anti-androgen) in mCRPC (Phase 3)
• PSMA radioligand therapy (177Lu and newer 225Ac):
  • NCT07611110 - VECTRA-01: AZD2265 (FPI-2265, 225Ac-PSMA-I&T alpha radioligand) vs SOC in PSMA-positive mCRPC (Phase 3)
  • NCT06855277 - AAA817 (225Ac-PSMA-617) + ARPI vs SOC in PSMA-positive mCRPC, first-line setting (Phase 3)
  • NCT06780670 - AAA817 vs standard of care in previously treated PSMA-positive mCRPC after 177Lu-PSMA (Phase 2/3)
  • NCT06520345 - ProstACT Global: 177Lu-TLX591 + SOC vs SOC alone in mCRPC (Phase 3)
• Antibody-drug conjugates:
  • NCT06925737 - Ifinatamab deruxtecan (I-DXd, MK-2400) in metastatic prostate cancer (Phase 3)
  • NCT07641855 - BL-B01D1 combination therapy in mCRPC (Phase 2/3, not yet recruiting)
• Post-NHA chemotherapy comparator:
  • NCT07632690 - QLC5508 vs Docetaxel in mCRPC after progression on novel hormonal agents (Phase 3)
  • NCT07365995 - BNT324 vs Docetaxel in mCRPC (Phase 3, activated 2026-06-27 — BioNTech ADC challenger to docetaxel post-NHA standard, joining QLC5508 as a second Phase 3 in the mCRPC post-NHA chemo-comparator space)
• Platform / biomarker-driven:
  • NCT03903835 - ProBio: Biomarker-driven multi-arm platform trial in metastatic prostate cancer (Phase 3)

BRCA / HRR-Mutated Prostate Cancer

For men with germline or somatic BRCA1/2 or other HRR-pathway mutations. Olaparib + abiraterone is already approved first-line in BRCA-mutated mCRPC; trials below extend PARP and platinum strategies earlier in the disease course:

• NCT06952803 - Saruparib (AZD5305) + standard RT/ADT vs Placebo + RT/ADT in high-risk localized BRCA-mutated prostate cancer (Phase 3)
• NCT07591467 - Carboplatin-enhanced therapy in BRCA-mutated or neuroendocrine-differentiated aggressive metastatic castration-sensitive prostate cancer (Phase 3, not yet recruiting)

Biochemical Recurrence / Oligometastatic

• NCT04794777 - Salvage RT vs PSMA PET/CT-targeted treatment in relapsing prostate cancer (Phase 3)
• NCT05352178 - Metastasis-directed therapy for oligorecurrent prostate cancer (Phase 3)
• NCT04787744 - Standard systemic therapy ± PET-directed local therapy for oligometastatic prostate cancer (Phase 2/3)
• NCT04423211 - Apalutamide + PSMA PET-guided targeted radiation for BCR (Phase 3)
• NCT05939414 - 177Lu-vipivotide tetraxetan vs Observation in PSMA+ oligometastatic prostate cancer (Phase 3)
• NCT06276465 - Darolutamide ± radiation for CRPC with metastases on functional imaging (Phase 3)

Localized / Post-Surgery

• NCT05116475 - Darolutamide + ADT + radiation in newly diagnosed prostate cancer with limited metastases (Phase 3)
• NCT06274047 - PROSTATE-IQ: Personalized apalutamide treatment post-operative (Phase 3)
• NCT03678025 - Standard systemic therapy ± definitive treatment in metastatic prostate cancer (Phase 3)
• NCT05946213 - Shorter duration vs usual radiation in high-risk prostate cancer (Phase 3)

Novel Approaches

• Alpha-emitter PSMA radioligand therapy: First Phase 3 trials of 225Ac-PSMA agents — AZD2265 / FPI-2265 (VECTRA-01) and AAA817 / 225Ac-PSMA-617 — moving beyond the established beta-emitter 177Lu-PSMA-617
• Bispecific T-cell engagers: Xaluritamig (STEAP1xCD3) and pasritamig (PSMAxCD3) — first BiTEs reaching Phase 3 in prostate cancer. Xaluritamig now being tested earlier in chemo-naive mCRPC (with abiraterone) and pasritamig is in late-line and docetaxel-combination Phase 3s
• PSMA radioligand therapy expansion: Moving from late-line mCRPC into first-line mCRPC (AAA817 + ARPI), de novo mHSPC with poor PSA response (PEACE6), and oligometastatic settings (177Lu-vipivotide vs observation)
• AR-pathway intensification through new mechanisms: Opevesostat (CYP11A1 inhibitor), mevrometostat (EZH2 inhibitor), rezvilutamide, HC-1119 — targeting AR signaling through orthogonal pathways
• PARP earlier in disease course: Saruparib + RT/ADT in high-risk localized BRCA-mutated prostate cancer — moving PARP from mCRPC into the curative-intent setting for BRCA-positive men
• PSMA PET-guided treatment: Multiple Phase 3 trials using PSMA PET to guide radiation, surgery, and systemic therapy decisions

Frequently Asked Questions